NCT05773144 Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
| NCT ID | NCT05773144 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AdventHealth Translational Research Institute |
| Condition | Colonic Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 219 participants |
| Start Date | 2023-06-01 |
| Primary Completion | 2027-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 219 participants in total. It began in 2023-06-01 with a primary completion date of 2027-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To goal of this clinical trial is to quantify the dose-response effects of aerobic exercise training compared to attention control on chemotherapy relative dose intensity in colon cancer survivors.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Histologically confirmed stage II or III colon cancer * Completed surgical resection with curative intent * Plan to initiate chemotherapy * Engage in \<60 minutes per week of moderate- to vigorous-intensity structured aerobic exercise * No planned major surgery during the study period * Readiness to exercise, as determined by a modified version of the Physical Activity Readiness Questionnaire * Can walk 400 meters * Can read and speak English * Ability to provide written informed consent * Provide written approval by qualified healthcare professional * Willing to be randomized Exclusion Criteria: * Evidence of metastatic colon cancer * Concurrently actively treated other (non-colon) cancer * Currently pregnant, breastfeeding, or planning to become pregnant within the next 24 weeks * Currently participating in another study with competing outcomes * Any other condition that, in the opinion of the investigator, would preclude participation or successful compliance with the protocol * Any other situation that, in the opinion of the investigator, would negatively impact subject safety or successful compliance with the protocol
Contact & Investigator
Justin C. Brown, Ph.D.
PRINCIPAL INVESTIGATOR
AdventHealth
Frequently Asked Questions
Who can join the NCT05773144 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colonic Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05773144 currently recruiting?
Yes, NCT05773144 is actively recruiting participants. Contact the research team at Justin.Brown4@AdventHealth.com for enrollment information.
Where is the NCT05773144 trial being conducted?
This trial is being conducted at Oakland, United States, Orlando, United States, Boston, United States.
Who is sponsoring the NCT05773144 clinical trial?
NCT05773144 is sponsored by AdventHealth Translational Research Institute. The principal investigator is Justin C. Brown, Ph.D. at AdventHealth. The trial plans to enroll 219 participants.